Stock listing
CSE:SONA Sona Nanotech, Inc. Stock
Home listing (CSE) of Sona Nanotech, Inc.
Follow Sona Nanotech, Inc. into a list and get an email when it puts out news.
Share price · CSE:SONA
$0.255 CAD 0.000 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.255 – $0.260 CADNov 20, 2026
- Volume
- 29,491 sharesNov 20, 2026
- Market cap
- $31.31M CADAt the close on Nov 20, 2026 · price × 122.8M shares outstanding
- 52-week range
- $0.240 – $0.600 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $13,549 CADMedian day 21,998 shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:SONA · Home | $0.255 CAD | 0.000 (0.0%) | 29,491 | $0.260 | $0.260 | $0.255 | $0.255 | Close on Nov 20, 2026 |
| OTC:SNANF | $0.197 USD | +0.015 (+8.3%) | 850 | $0.197 | $0.197 | $0.197 | $0.182 | Close on Nov 13, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · CSE:SONA · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.255 | 0.000 | 0.0% | $0.260 | $0.260 | $0.255 | 29,491 | |
| $0.255 | +0.005 | +2.0% | $0.260 | $0.270 | $0.255 | 17,900 | |
| $0.250 | -0.010 | -3.8% | $0.260 | $0.270 | $0.240 | 9,897 | |
| $0.260 | -0.010 | -3.7% | $0.275 | $0.275 | $0.260 | 5,454 | |
| $0.270 | +0.020 | +8.0% | $0.260 | $0.270 | $0.260 | 12,129 | |
| $0.250 | -0.030 | -10.7% | $0.260 | $0.260 | $0.250 | 68,320 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.280 | $0.280 | 0 | |
| $0.280 | 0.000 | 0.0% | $0.285 | $0.285 | $0.280 | 8,100 | |
| $0.280 | -0.015 | -5.1% | $0.265 | $0.280 | $0.260 | 83,181 | |
| $0.295 | -0.005 | -1.7% | $0.295 | $0.295 | $0.295 | 645 | |
| $0.300 | +0.015 | +5.3% | $0.285 | $0.300 | $0.275 | 56,602 | |
| $0.285 | 0.000 | 0.0% | $0.285 | $0.285 | $0.280 | 120,306 | |
| $0.285 | 0.000 | 0.0% | $0.285 | $0.285 | $0.270 | 131,576 | |
| $0.285 | +0.005 | +1.8% | $0.285 | $0.285 | $0.270 | 10,723 | |
| $0.280 | 0.000 | 0.0% | $0.285 | $0.285 | $0.280 | 26,130 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.280 | $0.280 | 0 | |
| $0.280 | +0.005 | +1.8% | $0.265 | $0.285 | $0.265 | 13,572 | |
| $0.275 | +0.015 | +5.8% | $0.265 | $0.285 | $0.260 | 97,032 | |
| $0.260 | -0.025 | -8.8% | $0.270 | $0.270 | $0.260 | 49,472 | |
| $0.285 | +0.020 | +7.5% | $0.280 | $0.285 | $0.280 | 17,624 | |
| $0.265 | -0.025 | -8.6% | $0.290 | $0.290 | $0.260 | 164,844 | |
| $0.290 | +0.010 | +3.6% | $0.290 | $0.295 | $0.290 | 9,500 | |
| $0.280 | 0.000 | 0.0% | $0.310 | $0.310 | $0.280 | 51,015 | |
| $0.280 | -0.040 | -12.5% | $0.320 | $0.320 | $0.280 | 92,900 | |
| $0.320 | -0.005 | -1.5% | $0.325 | $0.330 | $0.310 | 63,822 | |
| $0.325 | +0.020 | +6.6% | $0.310 | $0.335 | $0.300 | 343,020 | |
| $0.305 | -0.015 | -4.7% | $0.325 | $0.325 | $0.300 | 103,218 | |
| $0.320 | +0.020 | +6.7% | $0.310 | $0.320 | $0.310 | 37,330 | |
| $0.300 | -0.015 | -4.8% | $0.330 | $0.330 | $0.300 | 22,756 | |
| $0.315 | -0.015 | -4.5% | $0.315 | $0.320 | $0.315 | 79,100 | |
| $0.330 | +0.005 | +1.5% | $0.340 | $0.340 | $0.315 | 18,112 | |
| $0.325 | 0.000 | 0.0% | $0.325 | $0.330 | $0.325 | 5,150 | |
| $0.325 | -0.005 | -1.5% | $0.330 | $0.330 | $0.325 | 5,629 | |
| $0.330 | 0.000 | 0.0% | $0.330 | $0.330 | $0.330 | 1,704 | |
| $0.330 | +0.030 | +10.0% | $0.330 | $0.345 | $0.310 | 63,765 | |
| $0.300 | -0.030 | -9.1% | $0.340 | $0.340 | $0.300 | 106,175 | |
| $0.330 | 0.000 | 0.0% | $0.330 | $0.330 | $0.330 | 0 | |
| $0.330 | -0.005 | -1.5% | $0.360 | $0.360 | $0.330 | 1,630 | |
| $0.335 | -0.020 | -5.6% | $0.370 | $0.370 | $0.335 | 11,812 | |
| $0.355 | 0.000 | 0.0% | $0.355 | $0.365 | $0.355 | 36,800 | |
| $0.355 | -0.020 | -5.3% | $0.365 | $0.365 | $0.355 | 10,500 | |
| $0.375 | +0.020 | +5.6% | $0.370 | $0.375 | $0.370 | 8,500 | |
| $0.355 | 0.000 | 0.0% | $0.355 | $0.355 | $0.355 | 2,047 | |
| $0.355 | +0.005 | +1.4% | $0.355 | $0.355 | $0.355 | 2,073 | |
| $0.350 | -0.010 | -2.8% | $0.350 | $0.350 | $0.350 | 3,551 | |
| $0.360 | +0.010 | +2.9% | $0.360 | $0.370 | $0.360 | 62,705 | |
| $0.350 | 0.000 | 0.0% | $0.360 | $0.370 | $0.350 | 68,750 | |
| $0.350 | +0.005 | +1.4% | $0.360 | $0.360 | $0.345 | 77,822 | |
| $0.345 | -0.010 | -2.8% | $0.365 | $0.365 | $0.345 | 49,140 | |
| $0.355 | +0.005 | +1.4% | $0.370 | $0.370 | $0.355 | 1,418 | |
| $0.350 | -0.010 | -2.8% | $0.375 | $0.375 | $0.350 | 43,794 | |
| $0.360 | -0.020 | -5.3% | $0.380 | $0.380 | $0.360 | 17,065 | |
| $0.380 | +0.015 | +4.1% | $0.370 | $0.380 | $0.370 | 57,200 | |
| $0.365 | +0.005 | +1.4% | $0.360 | $0.365 | $0.360 | 5,001 | |
| $0.360 | 0.000 | 0.0% | $0.355 | $0.365 | $0.355 | 21,240 | |
| $0.360 | +0.015 | +4.3% | $0.345 | $0.360 | $0.345 | 17,474 | |
| $0.345 | +0.010 | +3.0% | $0.365 | $0.365 | $0.345 | 38,100 | |
| $0.335 | -0.025 | -6.9% | $0.365 | $0.365 | $0.330 | 102,703 | |
| $0.360 | +0.005 | +1.4% | $0.360 | $0.365 | $0.355 | 10,000 | |
| $0.355 | +0.005 | +1.4% | $0.355 | $0.365 | $0.350 | 40,830 | |
| $0.350 | 0.000 | 0.0% | $0.350 | $0.350 | $0.350 | 1,500 | |
| $0.350 | -0.005 | -1.4% | $0.350 | $0.355 | $0.350 | 13,525 | |
| $0.355 | +0.005 | +1.4% | $0.355 | $0.355 | $0.345 | 76,700 | |
| $0.350 | 0.000 | 0.0% | $0.365 | $0.365 | $0.335 | 71,913 |
- Ticker
- CSE:SONA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- CSE
- Currency
- CAD
What changed lately
Latest news release · Oct 13, 2026
Sona Nanotech Announces Chief Technology Officer and Annual Options Grants
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 24 slides
Latest news
Sona Nanotech Announces Chief Technology Officer and Annual Options Grants
Oct 13, 2026
Closed $0.32 (+6.7%) on Oct 13, 2026
Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September 17th
Sep 11, 2026
Closed $0.345 (-2.8%) on Sep 11, 2026
Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds
Aug 10, 2026
Closed $0.34 (+3.0%) on Aug 11, 2026
SONA Nanotech to arrange private placement financing
Jul 31, 2026
Closed $0.28 (0.0%) on Aug 4, 2026
Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors
Jun 11, 2026
Closed $0.28 (+3.7%) on Jun 11, 2026
Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma
May 5, 2026
Closed $0.305 (+1.7%) on May 5, 2026
Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences
Apr 27, 2026
Closed $0.31 (0.0%) on Apr 27, 2026
Sona Nanotech Announces Appointment of Two Leading Oncologists To Its Scientific Advisory Board
Apr 16, 2026
Closed $0.31 (-3.1%) on Apr 16, 2026
Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies
Apr 13, 2026
Closed $0.32 (+6.7%) on Apr 13, 2026
Sona Nanotech, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 45 in all · newest Oct 13, 2026 · oldest 2023
- Decks
- 17 decks · latest September 2026
Where Sona Nanotech, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:SONA · Home listing · This page | CSE | Canada | CAD |
| Cboe Canada:SONA | Cboe Canada | Canada | CAD |
| OTC:SNANF | OTC | United States | USD |
Cash and shares
Sep 16, 2026 · Sona Nanotech — Investor Presentation (September 2026)
- Shares outstanding
- 122.8 million
Valuation
Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026
- Enterprise value
- $31.64M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P/TSX Composite
- 0.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sona Nanotech, Inc. · CSE:SONA | US$21.84M | US$22.06M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| BioNxt Solutions Inc · CSE:BNXT | US$22.78M | US$22.72M | n/a | n/a | n/a | n/a | n/a | n/a | 0.22 |
| Polyrizon Ltd. · NASDAQ:PLRZ | US$22.61M | US$7.56M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.67 |
| ME Therapeutics Holdings, Inc. · CSE:METX | US$22.25M | US$21.88M | n/a | n/a | n/a | 49.5× | n/a | 0.0× | 0.52 |
| CervoMed Inc. · NASDAQ:CRVO | US$22.09M | US$2.49M | n/a | 285× | n/a | 1.3× | n/a | 0.0× | 1.97 |
| Mendus AB · OMXSTO:IMMU | US$21.76M | US$17.65M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | n/a |
| Metagenomi Therapeutics, Inc. · NASDAQ:MGX | US$21.36M | −US$44.10M | n/a | −6.2× | n/a | 0.2× | n/a | 0.4× | 1.65 |
| NanoGroup SA · GPW:NNG | US$21.32M | US$18.78M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Cel-Sci Corporation · AMEX:CVM | US$21.28M | US$14.76M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 1.13 |
| ZYUS Life Sciences Corporation · TSXV:ZYUS | US$20.92M | US$25.65M | n/a | 98.4× | n/a | n/a | n/a | n/a | -0.02 |
| Xbrane Biopharma AB · OMXSTO:XBRANE | US$20.88M | US$23.48M | n/a | 1.9× | n/a | 0.4× | −49.0% | 0.1× | n/a |
| Median of the others | US$21.56M | US$18.22M | 50.1× | 1.1× | −49.0% | 0.0× | 0.67 |
Team and board
Officers
| Officer | Role |
|---|---|
| David Regan | CEO |
| Robert Randall | Chief Financial Officer |
| Greg Young | VP Corporate Services |
| Fiona Marshall | Manager |
| Gerry Marangoni | Co-Founder |
| Kulbir Singh | Co-Founder & Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Mark Lievonen | Chair |
| Gerry Marangoni | Co-Founder |
| James Megann | Director |
| Jonathan Trites | Board-certified Specialist |
| Len Pagliaro | Director |
| Michael A. Fleming | Director |
| Neil Fraser | Director |
| Walter Strapps | Director |
| Wayne Myles | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2025 | Sep 29, 2025 · After close | 0.0% |
| Q2 2025 | Jun 26, 2025 · After close | +8.7% |
| Quarter to Jan 31, 2021 | Mar 1, 2021 · After close | −11.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 24 slides | September 2026 |
| Investor Presentation (May 2026) | Investor deck | 28 slides | May 2026 |
| Investor Presentation (October 2025) | Investor deck | 23 slides | October 2025 |
| Investor Presentation (May 2025) | Investor deck | 26 slides | May 2025 |
| Investor Presentation (March 2025) | Investor deck | 26 slides | March 2025 |
| Investor Presentation (August 2024) | Investor deck | 24 slides | August 2024 |
| Investor Presentation (July 2024) | Investor deck | 21 slides | July 2024 |
| Investor Presentation (May 2024) | Investor deck | 26 slides | May 2024 |
| Investor Presentation (April 2024) | Investor deck | 23 slides | Apr 12, 2024 |
| Investor Presentation (April 2024) | Investor deck | 21 slides | Apr 12, 2024 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2023) | Investor deck | 23 slides | November 2023 |
| Investor Presentation (September 2023) | Investor deck | 24 slides | September 2023 |
| Investor Presentation (January 2023) | Investor deck | 21 slides | January 2023 |
| Shareholder Meeting (April 2021) | Shareholder meeting | 19 slides | April 2021 |
| Investor Presentation (November 2020) | Investor deck | 20 slides | November 2020 |
| Investor Presentation (November 2020) | Investor deck | 22 slides | November 2020 |
| Investor Presentation (May 2020) | Investor deck | 13 slides | May 2020 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of common shares Announced: up to C$2.4M · C$0.3 a share Insiders: Insiders and certain other existing shareholders may also subscribe for Shares Use of proceeds: Studies and R&D to advance its Targeted Hyperthermia Therapy oncology treatment toward the clinic, and general working capital | Jul 31, 2026 | US$1.71M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | |||||||
| Gross profit | 0 | 0 | 0 | |||||||
| Research and development | 847.0K | 277.9K | 455.3K | 70.9K | 154.1K | 3.61M | 51.9K | 136.1K | 55.6K | 34.3K |
| Selling, general and administrative | 1.75M | 1.91M | 1.93M | 3.21M | 10.5M | 5.51M | 1.63M | 5.06M | 357.3K | 509.4K |
| Operating income | -3.44M | -2.92M | -2.62M | -2.73M | -10.7M | -9.13M | -1.66M | -5.18M | -357.7K | -591.5K |
| Depreciation and amortization | 720.0K | 14.0K | 36.8K | 60.3K | 65.6K | 66.4K | 51.1K | 27.8K | 3.80K | 795 |
| EBITDA | -2.72M | -2.90M | -2.58M | -2.67M | -10.7M | -9.06M | -1.60M | -5.15M | -353.9K | -590.7K |
| Interest expense | 38.6K | 4.13K | 13.1K | 5.27K | 20.8K | 25.6K | 145.6K | 75.6K | 0 | 0 |
| Income before tax | -3.25M | -2.70M | -2.50M | -2.36M | -10.4M | -6.27M | -2.52M | -5.20M | -2.28M | -642.8K |
| Income tax | 0 | 0 | 0 | |||||||
| Net income | -3.25M | -2.70M | -2.50M | -2.36M | -10.4M | -6.27M | -2.52M | -5.20M | -2.28M | -642.8K |
| Earnings per share, basic | -0.03 | -0.02 | -0.03 | -0.03 | -0.16 | -0.10 | -0.04 | -0.10 | -0.03 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 122.0K | 1.85M | 109.4K | 155.4K | 1.18M | 102.8K | 580.7K | 1.80M | 428.9K | 19.0K |
| Short-term investments | 4.00K | 4.00K | 6.00K | 9.00K | 13.0K | 8.00K | 4.50K | 5.50K | 355.6K | 561.4K |
| Receivables | 105.0K | 97.2K | 54.5K | 252.8K | 132.8K | 61.8K | 16.0K | 277.0K | 141.0K | 95.7K |
| Current assets | 298.6K | 2.00M | 263.3K | 470.0K | 1.41M | 548.0K | 618.0K | 2.10M | 315.8K | 142.9K |
| Property, plant and equipment | 0 | 14.0K | 50.7K | 111.1K | 176.7K | 241.2K | 1.08M | 20.3K | 590 | |
| Total assets | 1.33M | 3.75M | 2.75M | 520.8K | 1.52M | 724.6K | 859.2K | 3.18M | 1.74M | 4.85M |
| Accounts payable | 906.9K | 647.3K | 900.8K | 331.7K | 576.0K | 2.07M | 417.2K | 727.5K | 238.0K | 551.3K |
| Current liabilities | 1.06M | 842.3K | 1.06M | 420.2K | 2.05M | 4.16M | 1.21M | 2.44M | 962.0K | 664.8K |
| Long-term debt | 307.7K | 394.7K | 527.7K | 608.5K | 700.8K | 0 | 666.8K | 543.2K | 172.3K | 380.7K |
| Total debt | 1.16M | 962.6K | 334.6K | |||||||
| Total liabilities | 1.37M | 1.24M | 1.59M | 1.03M | 2.75M | 4.16M | 1.88M | 2.98M | 1.71M | 2.17M |
| Shareholders' equity | -38.8K | 2.51M | 1.16M | -507.9K | -1.22M | -3.44M | -1.02M | 199.1K | 24.5K | 2.68M |
| Shares outstanding | 112.9M | 111.7M | 95.1M | 69.0M | 65.2M | 61.3M | 57.7M | 53.5M | 88.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M | -4.05M | -1.36M | -1.55M | -244.2K | -328.1K |
| Capital spending | 0 | 0 | 0 | 0 | 0 | -376.6K | -158.7K | -145.7K | -23.5K | -651 |
| Free cash flow | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M | -4.75M | -1.52M | -1.54M | -175.8K | -328.8K |
| Cash from investing | 0 | 14.6K | 0 | -694.0K | -158.7K | -145.7K | -23.5K | -651 | ||
| Cash from financing | 228.4K | 3.70M | 1.20M | 777.6K | 4.89M | 4.27M | 298.6K | 3.33M | 395.8K | 336.5K |
| Share buybacks | 3.70M | 1.01M | 585.1K | 4.34M | 264.7K | 41.3K | 2.44M | 260.0K | ||
| Change in cash | -1.73M | 1.75M | -46.0K | -1.03M | 1.08M | -477.9K | -1.22M | 1.63M | 128.1K | 7.75K |
Cap table
Built by 6ix from Sona Nanotech, Inc.’s releases · as of Oct 13, 2026
- Common shares
- 122,798,625
- Fully diluted
- 125,173,625
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 122,798,625 | Jul 31, 2026 |
| Options and RSUs | 2,375,000 | Oct 13, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · C$0.35 · expire about Oct 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 122,798,625 |
| Jul 31, 2026 | 114,375,253 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Regan | CEO · Since at least Sep 11, 2026 |
| Fiona Marshall | Manager · Since at least Nov 4, 2026 |
| Gerry Marangoni | Co-Founder · Since at least Nov 4, 2026 |
| Greg Young | VP Corporate Services · Since at least Sep 11, 2026 |
| James Megann | Director · Since at least Nov 5, 2026 |
| Jonathan Trites | Board-certified Specialist · Since at least Apr 16, 2026 |
| Kulbir Singh | Co-Founder & Chief Technology Officer · Since at least Oct 13, 2026 |
| Len Pagliaro | Director · Since at least Oct 20, 2025 |
| Mark Lievonen | Chair · Since at least Jun 11, 2026 |
| Michael A. Fleming | Director · Since at least Jun 11, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Neil Fraser | Director · Since at least Nov 5, 2026 |
| Robert Randall | Chief Financial Officer · Since at least Nov 5, 2026 |
| Walter Strapps | Director · Since at least Nov 5, 2026 |
| Wayne Myles | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Sona Nanotech, Inc.